– Una vez finalizada la inscripción a VIRAGE, el ensayo clínico de Fase 2b de VCN-01 para el adenocarcinoma pancreático ductal (PDAC) metastásico, los datos preliminares se esperan para el segundo trimestre de 2025 –
Posted: 2025-03-08 07:56:00
Article Tools/Herramientas de artículos
+ Larger Font/Fuente más grande | - Smaller Font/Fuente más pequeñaGlobe NewsWire News Distribution Service
Press Release: Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del ejercicio 2024
- Details
- Written by Globe NewsWire Press Releases
- Category: Globe NewsWire News Distribution Service
– Una vez finalizada la inscripción a VIRAGE, el ensayo clínico de Fase 2b de VCN-01 para el adenocarcinoma pancreático ductal (PDAC) metastásico, los datos preliminares se esperan para el segundo trimestre de 2025 –
Posted: 2025-03-08 07:56:00
Listen to this article. Speaker link opens in a new window.
Related Bing News Search Results
Press Release: Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del ejercicio 2024 - Newscast
Theriva puts GvHD drug on back burner to focus on oncolytic adenovirus
Fri, 07 Mar 2025 00:47:00 GMT Theriva Biologics is putting more of its eggs in the VCN-01 basket as it unveils a change-up in its R&D focus. | Theriva Biologics is putting more of its eggs in the VCN-01 basket as it unveils a ...Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results
Thu, 06 Mar 2025 14:10:00 GMT Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected ...Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results
Thu, 06 Mar 2025 13:10:00 GMT About Theriva™ Biologics, Inc. Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas ...Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual
Wed, 05 Mar 2025 13:20:00 GMT Q1 Investor Summit Virtual Format: Presentation Presenter: Steve Shallcross, CEO and Manel Cascallo, PhD., General Director Presentation Date and Time: Tuesday, March 11, 2025, 12:30 PM ET Webcast: ...Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual
Wed, 05 Mar 2025 13:04:00 GMT Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company ...
Related Product Search/Búsqueda de productos relacionados
